Concomitant use of ranolazine and conventional anti-anginal agents
Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.
Related articles
07/26/2017 - Gender-specific dosage should be included on labels to prevent adverse effects - Sian Claire Owen, Medical Journalist for Cardio Debate
06/27/2016 - Ranolazine for management of microvascular angina - Prof Juan Carlos Kaski, St George's, University of London, UK
10/30/2015 - True advances in the treatment of heart failure - Dr Giuseppe Rosano, Director, Centre for Clinical and Basic Research, Dept of Medical Sciences IRCCS San Raffaele, Roma, Italy
09/02/2015 - Long QT syndrome and epilepsy -
06/26/2015 - Management of angina and the role of Ranolazine in the context of the NICE guidelines -
06/26/2015 - Clinical cases where an indication for ranolazine may exist - Dr Rajan Sharma, St Geroge's University of London
Leave a Reply
You must be logged in to post a comment.